Drug intelligence / Profile preview

BPG1438

Development stage: Preclinical
Lead developer: Berg

Overview

BPG1438 is an early-stage oncology drug candidate being developed by BPGbio (formerly Berg Health). The compound was identified using BPGbio's proprietary Interrogative Biology® platform, which integrates artificial intelligence with multi-omic data—including proteomics, lipidomics, and metabolomics—to identify novel therapeutic targets and biomarkers. As of early 2024, BPG1438 is categorized within the company's drug discovery programs. Specific details regarding its molecular target, drug modality, and mechanism of action remain proprietary and have not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on BPG1438.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPG1438.

Explore the full profile